by the classifications of Gordon 3 and of Nicolle and his associates. 4 Briefly stated they distinguish also two main types of meningococci designated either Types I and II or A and B. Gordon also recognizes Subtypes III and IV, one affiliating with Type II and the other with Type I, and Nicolle equally distinguishes two such types, C and D, which show similar affiliations.
The serological subdivision of the meningococcus into varieties or types has undoubtedly marked a forward step in our knowledge of the causation and specific treatment of epidemic meningitis. It may, however, perhaps be regarded as of questionable value to set up too many minor varieties or types. The conditions are not dissimilar to those existing among the bacilli of dysentery with which we have long been familiar. In both instances the bacterial groups--meningococci and dysentery bacilli--seem still to be in a state of specific flux. In the case of meningococcus this fact is made especially apparent by the study of carrier strains which show even greater serological fluctuation than do the strains obtained from the inflamed meninges. 5
However, the present chief interest centers around the establishment of a test of therapeutic efficiency in antimeningococcic serum. It does not yet appear feasible to treat epidemic meningitis on the basis of monovalent sera adapted in every instance to the particular type or variety of meningococcus inducing the infection. Nor does it seem necessary to attempt this. There are no insuperable difficulties in the way of preparing an adequate polyvalent antimeningococcic serum in which not only the two main kinds of antibodies are sufficiently represented but also the main subvarieties or types as well Meningococci do not exhibit such strict serological specificity as we have become familiar with in regard to the types of pneumococci. 6 On the contrary, there is much overlapping of antibody 3 Gordon, M. H., Great Britain National Health Insurance, Med. Research Com., Special Rep. Series, No. 3, 1917, 10. 4 Nicolle, M., Debains, E., and Jouan, C., Ann. Inst. Pasteur, 1918, xxxii, 150. Eastwood, A., Rep. Local Gov. Bd. Pub. Health and Med. Subjects, 1917 , N.S. cxiv, 1. Griffith, F., ibid., 52. Scott, W. M., ibid., 111. (See also J. Hyg., 1918, xvii, 63, 124, 191.) Gordon, M. H., J. Hyg., 1918, xvii, 290. s Dochez, A. R., and Gillespie, L. J., J. Am. Med. Assn., 1913, lxi, 727. reactions, a fact which affects undoubtedly the wide therapeutic applicability of the antimeningococcic serum. In spite of this overlapping it is imperative that a standard should be established which will afford a measure of the therapeutic efficacy of given samples of the serum. An efficient sample of the serum should contain definite amounts of antibodies for the principal varieties and the main subvarieties or types of the meningococcus. There will be no disagreement as to the two main types, while differences of opinion may arise as to the main subvarieties. As regards the latter it will be safe to follow Gordon's classification which appears to express the essential fact. Accordingly the polyvalent antimeningococcic serum should be prepared with at least four properly chosen cultures of the meningococcus. This is the point of view arrived at by the New York State Department of Health, which has adopted and is enforcing in the State a standard based on agglutination titerJ
In choosing a standard of value for the antimeningococcic serum certain questions at once arise. The first relates to the particular antibody on which therapeutic activity depends. The point at issue with an antibacterial serum, as represented by the antimeningococcic serum, is far more complex than with the ordinary antitoxic sera. According to present beliefs the antimeningococcic serum acts (a) by increasing phagocytosis of the meningococcus, 8 (b) by neutralizing endotoxin, 9 (c) by injuring directly the meningococci and impairing their power of propagation? ° It remains, therefore, to be determined whether any one criterion will suffice as a measure of these several forms of activity.
The methods employed to effect the standardization of the serum have from time to time undergone change. Thus there have been employed successively (a) opsonin content, n (b) complement-fixing Off. Bull., New York State Dept. Health, 1918 , iii, No. 5. 8Jochmann, Deutsch. reed. Woch., 1911 , xxxvii, 1733 . Flexner, S., J. Exp. Med., 1907 , ix, 168. Flexner, S., and Amoss, H. L., J. Exp. Med., 1916 , xxiii, 683. 9 Flexner, S., J. Exp. Med., 1907 , ix, 168. 10 Flexner, J. Exp. Med., 1907 . Flexner, S., and Jobling, J. W., J. Exp. Med., 1908 , x, 141. 11 Jobling, J. W., J. Exp. Med., 1909 titery (c) agglutinin content) 3 (d) antiendotoxic value) 4 and (e) protective power. 15
The discrimination of parameningococcus from the regular meningococcus has automatically rendered the opsonic and complementbinding methods obsolete, since they do not suffice for the separate determination of the discrete antibodies. In practice, the discussion of standards has narrowed itself down to the relative merits of agglutinins or protective power as a measure of value.
It is desirable to state here that agglutination is the method of choice for standardization, since it alone gives clear distinctions between the types and varieties of meningococci. Its employment has been questioned on the ground that as the therapeutic action of ~he serum is probably not a function of the agglutinin, antibody may not be a measure of therapeutic efficacy. An effort is being made, therefore, to substitute for the agglutinin content of the serum the protective power.
In endeavoring to set up a standard of protection, account must, in the first instance, be taken of the small and variable pathogenic action of the meningococci. This fact has indeed been generally recognized by investigators. While certain small animals, such as young guinea pigs weighing about 100 gm. 1. and mice, will often succumb to intraperitoneal inoculations of moderate doses of cultures of meningococci, yet their reaction is variable, and fluctuation in virulence of the cultures is common.
EXPERIMENTAL.
Recently, therefore, Hitchens and Robinson 15 have proposed a method of standardization of the antimeningococcic serum based on its protective power. Because of the intrinsic importance of the subject for our military organizations and our civil communities, we have submitted the method to a critical examination. Hitchens and Robinson give in their paper what we regard as illustrative protocols of their experiments, from which they conclude that the "protection test parallels the extent of immunization more nearly than agglutination or complement fixation tests." They also state that "there seems to be a considerable degree of specificity in the test." A close study of their protocols fails, we believe, to carry conviction that, even in their hands, the test is either delicate or decisive. Unless it is both delicate and decisive, the object which they seek, namely that "if the amount of serum necessary to protect against one M. L. D.
of culture is considered as a unit, a rational and uniform method of standardizing antimeningococcus serum can be obtained," and "a dosage similar to that of antitoxic serum would be possible by such a method of standardization" is not attained.
In carrying out our experiments we have followed closely the conditions laid down by Hitchens and lkobinson. Thus a 16 hour growth of the meningococcus chosen was suspended in 1 cc. of dilute guinea pig serum and injected immediately in the indicated doses into the peritoneal cavity of white mice. In testing the action of samples of the antimeningococcic serum, 0.5 cc. was injected intraperitoneally 2 hours before the suspension of the culture was inoculated also intraperitoneally. Finally, in instances in which several cultures of a given meningococcus were made, they were all washed off with the dilute guinea pig serum and pooled before being used for inoculation. The volumes of serum and of bacterial suspension employed have always been 0.5 cc. each.
Series I. Regular Menlngococcus.
A regular meningococcus having a suitable degree of virulence was selected. The suspension was prepared in the manner indicated and injected immediately into the peritoneal cavity (Table I ). As Table  I shows, all but one of the injected mice died; but the order of their death did not conform to the dosage of the culture. When death took place within 24 hours the peritoneal cavity and heart's blood yielded many or innumerable colonies of meningococcus; when death was delayed the number of colonies grown from the heart's blood was often few.
The next experiment was made with normal serum as a control for the antimeningococcic serum, and in duplicate in order to cover in a measure the variable response of the mice to the inoculation (Table TABLE I * In the tables D. indicates died, S.R., sick and recovered, R., recovered.
II). The protocol brings out the facts (1) that the reaction of the mice to the inoculation is irregular, and (2) that normal horse serum exhibits no protective power against the meningococcus. Meningococci in large numbers were cultivated from the peritoneal cavity and heart's blood of the mice dying within 24 hours. Two experiments were made with polyvalent antimeningococcic serum of high titer according to the standard based on agglutinin content (Tables III and IV) . The serum also proved highly effective in the treatment of cases of epidemic meningitis. While Table III might be interpreted as giving evidence of protection, Table IV indicates an irregularity merely in the reaction of the mice, which cannot depend on protection. All the mice of Lot A which died yielded innumerable colonies of meningococcus from the peritoneal cavity and heart's blood. The next tests were made with a parameningococcus and the same samples of normal and antimeningococcic horse serum.
Series II. Parameningococcus.
The chief point which the experiment brings out is the striking irregularity of the protection tests in this instance (Tables V to VII). 
Series III. Intermediate Meningococcus.
The next test was carried out with an intermediate or irregular meningococcus tending slightly toward the regular (Tables VIII and  IX) . According to the agglutinin standard the polyvalent serum employed in this experiment was efficient; according to the protection test it is irregular in action and of practically no potency. 16 " " 10 " " 27½"
The final tests were carried out with two samples of monovalent antimeningococcic serum prepared in the horse, one for the normal or regular and the other for the parameningococcus. The horses yielding the two samples of serum had been under immunization for 12 and 9 weeks respectively. The agglutination titers of the sera at the time the protection tests were made was + to ++ at 1:500 dilution. According to the standard followed at The Rockefeller Institute the horses were not yet ready to yield therapeutic sera. The object was to ascertain whether they would show any evidence of protective power.
Series IV.
Monovalent Sera.
In Tables X and XI Lots 1 and 4 refer to the number of the regular culture of meningococcus used for inoculation. According to Table XI the monovalent serum would have to be regarded as devoid of antibodies, which is obviously, in view of the agglutination titer, not the case.
Perhaps it would have been well to carry the suspensions to a greater dilution; namely, to doses of 0.06 and 0.03 cc. Since these tests were performed during the period last spring of acute mouse shortage, the smaller doses were omitted, especially as in the control tests the mice receiving 0.06 cc. both survived. The fact that of those given the monovalent serum one survived and the other died merely emphasizes the irregularity of this test. spite of a moderate content of agglutinin and doubtless of therapeutic principles. The last two series of experiments were reversed so that the monovalent sera were made to react with their opposite cultures--the regular serum with para cultures and the para serum with regular cultures. Aside from what appeared to be an accidental survival, all the inoculated mice succumbed. DISCUSSION. In carrying out the experiments described in this paper no attempt was made to restudy, in an intensive manner, the general subject of the protective power of the antimeningococcic serum on animals. The purpose was merely to repeat the experiments of Hitchens and Robinson on which they base their argument for a protection standard for the antimeningococcic serum.
Our results failed wholly to confirm those of Hitchens and Robinson and conform to the earlier studies in indicating that infection tests carried out in laboratory animals with the meningococcus give extremely variable results, and that this factor of variability enters into and affects unfavorably the protection tests.
Investigators are generally agreed that the antimeningococcic serum possesses protective power against experimental meningococcic infection. This power is shown either by the survival of the inoculated and serum-treated animal or by reduction in the number of meningococci and increase in intensity of the phagocytosis within the peritoneal cavity. But not only are these reactions irregular in their occurrence but they are confined within relatively narrow limits and may succeed only when the minimum lethal dose of the culture inoculated is not exceeded. Reactions of this order are not well suited for purposes of standardization.
CONCLUSIONS.
Experiments were made for the purpose of testing the reaction of protection against infection as a measure of potency of antimeningococcic serum.
The results of the experiments were extremely variable and bore no relation to the quality of the sera as determined by the period of immunization of the horses from which they were obtained, or the indications of efficiency based upon their employment in human cases of epidemic meningitis.
The results also failed entirely to conform to the agglutination titer of the sera tested and to be affected by the different type forms of the meningococci.
We regard the protective power for laboratory animals of the antimeningococcic serum as an unsuitable index of its value in human medicine and as inferior to the agglutination titer as a standard of potency.
